The WHO Therapeutics and COVID-19: residing guideline accommodates the Group’s newest suggestions for using therapeutics within the therapy of COVID-19. The newest model of this residing guideline is on the market in pdf format (by way of the ‘Obtain’ button) and by way of a web based platform, and is up to date recurrently as new proof emerges.
This tenth model of the WHO residing guideline now accommodates 17 suggestions, together with two new suggestions concerning nirmatrelvir-ritonavir. No additional updates to the earlier current suggestions have been made on this newest model.
The WHO Therapeutics and COVID-19: residing guideline presently features a:
Different COVID-19 therapeutics which might be presently into account by WHO embody fluvoxamine, colchicine and anticoagulants. This guideline will likely be up to date if/when ample new proof warrants this.
Tips concerning using medicine to forestall (somewhat than deal with) COVID-19 are included in a separate doc, WHO Dwelling guideline: Medicine to forestall COVID-19, that may be accessed by way of a web based platform and in pdf format (or click on ‘PDF’ in prime proper nook of on-line platform).
Tips concerning the medical administration of COVID-19 sufferers are included in an additional doc, COVID-19 Scientific administration: Dwelling guideline, that may be accessed by way of a web based platform and in pdf format (or click on ‘PDF’ in prime proper nook of on-line platform).
To view earlier (now outdated) variations of this guideline, please see the hyperlinks under: